Skip to main content
SpringerLink
Log in

Major Randomized Clinical Trials in Cardiovascular Disease Prevention Presented at the 2019 American College of Cardiology Annual Scientific Session

  • Emerging Research (S. Virani, Section Editor)
  • Published:
Current Atherosclerosis Reports Aims and scope Submit manuscript

Abstract

Purpose of Review

At the 2019 American College of Cardiology annual scientific sessions, major randomized clinical trials in cardiovascular disease (CVD) prevention were presented.

Recent Findings

The CLEAR Wisdom trial examined the safety and efficacy of adding bempedoic acid to maximally tolerated statin for reducing low-density lipoprotein cholesterol. Post hoc analyses from the REDUCE-IT trial evaluated the efficacy of icosapent ethyl for lowering risk of total (first time and recurrent) CVD events. A sub-analysis of ODYSSEY OUTCOMES examined the effect of alirocumab on lipoprotein(a) lowering for reducing CVD risk. The CREOLE trial compared three different combination antihypertensive therapies for blood pressure lowering among black individuals in sub-Saharan Africa. The INFINITY trial examined the effect of intensive blood pressure control on progression of brain white matter changes and various components of mobility and cognitive function. Lastly, post hoc analyses from DECLARE-TIMI 58 evaluated the efficacy of dapagliflozin among patients with type 2 diabetes mellitus and heart failure or peripheral artery disease.

Summary

These trials hold future promise for novel agents aimed at reducing CVD burden among high-risk patients who continue to experience CVD events despite treatment with currently available guideline-directed therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. •• Goldberg A. Efficacy and Safety of Bempedoic Acid Added to Maximally Tolerated Statins in Patients with Hypercholesterolemia and High Cardiovascular Risk: The CLEAR Wisdom Trial. Am Coll Cardiol Annu Sci Sess (ACC 2019) New Orleans, LA. This study demonsrates the efficacy and safety of bempedoic acid for LDL-C lowring in high risk patients as compared to maximally tolerated statin.

  2. Jia X, Virani SS. CLEAR serenity trial: more clarity for the future of Bempedoic acid in patients unable to take statins? J Am Heart Assoc. 2019;8:e012352.

    PubMed  PubMed Central  Google Scholar 

  3. • Bhatt DL, Steg PG, Miller M, et al. Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia. N Engl J Med. 2019;380:11–22 This is the first study to show the efficacy of icosapent ethyl for reducing cardiovacular events in secondary prevention or high-risk primary prevention patients with type 2 diabetes mellitus with elevated triglycerides and relatively well-controlled LDL-C.

    Article  CAS  Google Scholar 

  4. •• Bhatt DL, Steg PG, Miller M, et al. Effects of Icosapent Ethyl on Total Ischemic Events: From REDUCE-IT. J Am Coll Cardiol. 2019; published online March. https://doi.org/10.1016/j.jacc.2019.02.032. This study is a post-hoc analysis of the REDUCE-IT trial demonstrating the efficacy of icosapent ethyl for reducing risk of total (first and subsequent) cardiovacular events.

    Article  CAS  Google Scholar 

  5. Musunuru K, Kathiresan S. Surprises from genetic analyses of lipid risk factors for atherosclerosis. Circ Res. 2016;118:579–85.

    Article  CAS  Google Scholar 

  6. Jia X, Kohli P, Virani SS. Omega-3 fatty acid and cardiovascular outcomes: insights from recent clinical trials. Curr Atheroscler Rep. 2019;21:1.

    Article  Google Scholar 

  7. Jia X, Akeroyd JM, Nasir K, Nambi V, Ballantyne CM, Petersen LA, et al. Eligibility and cost for Icosapent ethyl based on the REDUCE-IT trial. Circulation. 2019;139:1341–3.

    Article  Google Scholar 

  8. • Schwartz GG, Steg PG, Szarek M, et al. Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome. N Engl J Med. 2018;379:2097–107 This trial demonsrates the efficacy of alirocumab for lowering risk of cardiovascular outcomes in patients with recent acute coronary syndrome and suboptimal cholesterol control on maximally tolerated statin.

    Article  CAS  Google Scholar 

  9. •• V B. Lowering by Alirocumab Contributes to Event Reduction Independent of Low-Density Liporpotein Cholesterol in the ODYSSEY OUTCOMES Trial. Am Coll Cardiol Annu Sci Sess (ACC 2019) New Orleans, LA. This post-hoc analysis from ODYSSEY OUTCOMES shows that Lp(a) lowering with alirocumab reduces risk of cardioovacular outcomes independent of its LDL-C lowering effects.

  10. Jia X, Al Rifai M, Birnbaum Y, Smith SCJ, Virani SS. The 2018 cholesterol management guidelines: topics in secondary ASCVD prevention clinicians need to know. Curr Atheroscler Rep. 2019;21:20.

    Article  Google Scholar 

  11. •• Ojji DB, Mayosi B, Francis V, et al. Comparison of dual therapies for lowering blood pressure in black Africans. N Engl J Med. 2019; published online march. https://doi.org/10.1056/NEJMoa1901113. This study shows that treatment of hypertensive Black Africans with amlodipine plus perindopril or hydrochlorthiazide was more efficacious for lowering ambulating systolic blood pressure compared to perindopril and hydrochlorothiazide.

    Article  Google Scholar 

  12. •• White W. Primary Results of the Intensive versus Standard Ambulatory Blood Pressure Lowering to Lessen Functional Decline in the Elderly Trial (INFINITY). Am Coll Cardiol Annu Sci Sess (ACC 2019) New Orleans, LA. This study shows that intensive SBP lowering to <130 mmHg reduced white matter hypertensity progression but that this does not translate to improvement in mobility or cognition.

  13. • Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2019;380:347–57 This trial shows that dapagliflozin is not inferior but also not superior to placebo for reducing MACE in patients with type 2 diabetes mellitus with established ASCVD or multiple CVD risk factors.

    Article  CAS  Google Scholar 

  14. •• Kato ET, Silverman MG, Mosenzon O, et al. Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus. Circulation. 2019; published online March. https://doi.org/10.1161/CIRCULATIONAHA.119.040130. This subgroup analysis of DECLARE TIMI 58 shows that dapagliflozin reduces the risk of cardiovacular death or heart failure hospitalization in patients with HFrEF but not in patients without HFrEF.

    Article  CAS  Google Scholar 

  15. •• MP B. Dapagliflozin and Outcomes in Patients with Peripheral Artery Disease: Insights from DECLARE-TIMI 58. Am Coll Cardiol Annu Sci Sess (ACC 2019) New Orleans, LA, 2019. This subgroup analysis of DECLARE TIMI 58 shows that dapagliflozin reduces the risk of MACE simialrly in patients with and without peripheral artery disease.

  16. Jia X, Mehta PB, Ye Y, Alam M, Birnbaum Y, Bajaj M. SGLT2 inhibitors and cardiovascular outcomes: current perspectives and future potentials. Curr Diab Rep. 2018;18:63.

    Article  Google Scholar 

  17. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117–28.

    Article  CAS  Google Scholar 

  18. Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377:644–57.

    Article  CAS  Google Scholar 

Download references

Author information

Author notes

  1. Mahmoud Al Rifai and Xiaoming Jia contributed equally to this work.

Authors and Affiliations

  1. Department of Medicine, University of Kansas School of Medicine, Wichita, KS, USA

    Mahmoud Al Rifai

  2. Section of Cardiovascular Research, Department of Medicine, Baylor College of Medicine, Houston, TX, USA

    Xiaoming Jia & Salim S. Virani

  3. Department of Cardiac Imaging, Houston Methodist Hospital, Houston, TX, USA

    Mouaz H. Al-Mallah

  4. Minneapolis Heart Institute and Minneapolis Heart Institute Foundation, Minneapolis, MN, USA

    Michael D. Miedema

  5. Johns Hopkins Ciccarone Center for the Prevention of Heart Disease, Baltimore, MD, USA

    Seth S. Martin

  6. Health Policy, Quality and Informatics Program, Michael E. DeBakey Veterans Affairs Medical Center Health Services Research and Development Center for Innovations, 2002 Holcombe Boulevard, Houston, TX, 77030, USA

    Salim S. Virani

  7. Section of Cardiology, Michael E. DeBakey Veterans Affairs Medical Center, Houston, TX, USA

    Salim S. Virani

Authors
  1. Mahmoud Al Rifai
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Xiaoming Jia
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Mouaz H. Al-Mallah
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Michael D. Miedema
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Seth S. Martin
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Salim S. Virani
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Salim S. Virani.

Ethics declarations

Conflict of Interest

Mahmoud Al Rifai, Xiaoming Jia, Mouaz H. Al-Mallah, Michael D. Miedema, Seth S. Martin, and Salim S. Virani declare no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is part of the Topical Collection on Emerging Research

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Al Rifai, M., Jia, X., Al-Mallah, M.H. et al. Major Randomized Clinical Trials in Cardiovascular Disease Prevention Presented at the 2019 American College of Cardiology Annual Scientific Session. Curr Atheroscler Rep 21, 31 (2019). https://doi.org/10.1007/s11883-019-0789-3

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11883-019-0789-3

Keywords

Search

Navigation